Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors

Xiangchen Hu1†, Zhe Wang2†, Peng Su3, Qiqi Zhang2 and Youwei Kou1*

1Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China, 2Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China, 3Medical Research Center, Shengjing Hospital of China Medical University, Shenyang, China

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. At present, surgery is the first-line treatment for primary resectable GISTs; however, the recurrence rate is high. Imatinib mesylate (IM) is an effective first-line drug used for the treatment of unresectable or metastatic recurrent GISTs. More than 80% of patients with GISTs show significantly improved 5-year survival after treatment; however, approximately 50% of patients develop drug resistance after 2 years of IM treatment. Therefore, an in-depth research is urgently needed to reveal the mechanisms of secondary resistance to IM in patients with GISTs and to develop new therapeutic targets and regimens to improve their long-term prognoses. In this review, research on the mechanisms of secondary resistance to IM conducted in the last 5 years is discussed and summarized from the aspects of abnormal energy metabolism, gene mutations, non-coding RNA, and key proteins. Studies have shown that different drug-resistance mechanism networks are closely linked and interconnected. However, the influence of these drug-resistance mechanisms has not been compared. The combined inhibition of drug-resistance mechanisms with IM therapy and the combined inhibition of multiple drug-resistance mechanisms are expected to become new therapeutic options in the treatment of GISTs. In addition, implementing individualized therapies based on the identification of resistance mechanisms will provide new adjuvant treatment options for patients with IM-resistant GISTs, thereby delaying the progression of GISTs. Previous studies provide theoretical support for solving the problems of drug-resistance mechanisms. However, most studies on drug-resistance mechanisms are still in the research stage. Further clinical studies are needed to confirm the safety and efficacy of the inhibition of drug-resistance mechanisms as a potential therapeutic target.

KEYWORDS
gastrointestinal stromal tumor, imatinib, secondary imatinib resistance, drug-resistance mechanism, therapeutic targets
1 Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, originating from gastrointestinal pacemaker cells (interstitial cells of Cajal, ICC) or related stem cells (1, 2). GISTs are typically driven by mutations of the receptor tyrosine kinase oncogene (C-KIT) or the platelet-derived growth factor receptor alpha (PDGFRα), which account for more than 80% and 5%–10% of all cases of GIST, respectively (3–5). GISTs without KIT or PDGFRα mutations are known as wild-type GISTs (WT-GISTs), which account for 10%–15% of all cases of adult GISTs and up to 85% of all cases of pediatric GISTs (6–8). In this category, 20%–40% are characterized by the loss of succinate dehydrogenase complex (SDH-deficient GISTs), approximately 15% carry BRAF/RAS or NF1 mutations, and the remainder is referred to as KIT/PDGFRα/RAS-P WT-GISTs (or quadruple WT-GISTs) (9, 10). A careful examination for germline mutations is of great significance for all patients with WT-GISTs (11).

Analyses conducted using tissue microarrays have shown that the DOG1 gene is relatively specifically expressed in GISTs, regardless of the KIT or PDGFRA mutation status (12). A monoclonal antibody against DOG1 has been proven to be a highly sensitive specific marker for the diagnosis of GISTs, and its sensitivity is higher than that of KIT (13).

Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor (TKI) that targets KIT and PDGFRα for the treatment of unresectable or metastatic GISTs, which significantly improves the 5-year survival of patients (14, 15). The efficacy of IM varies among different KIT and PDGFRA mutation types, depending on the exons involved (16, 17). Approximately 14% of patients with GISTs are initially resistant to IM (18), whereas approximately 50% of patients develop resistance after 2 years of treatment, the so-called secondary resistance to IM (19). Therefore, it is important to clarify the mechanisms of secondary resistance to IM through research and develop new therapeutic targets and regimens to improve the long-term prognoses of patients with GISTs. A recent study demonstrated that IM specifically increases the expression of the complex II (SDH) protein in oxidative phosphorylation (OXPHOS) proteins by downregulating miR-483-3p (Figure 1A). This study demonstrated the molecular mechanism of increased OXPHOS protein expression induced by IM and confirmed the biological role of miR-483-3p in regulating energy metabolism after IM treatment (20). This review will focus on the discussion and summary of research on the mechanisms of secondary resistance to IM conducted in the last 5 years from the aspects of abnormal gene mutation, energy metabolism, non-coding RNA, and key proteins.

2 Mechanisms of secondary resistance to imatinib

2.1 Gene mutation and resistance to imatinib

Secondary KIT and PDGFRA mutations are the main causes of secondary resistance to IM in non–wild-type GIST (21, 22). In most cases of GIST, secondary KIT mutations reactivates KIT

![Figure 1](frontiersin.org)

**Figure 1**
Abnormal energy metabolism and resistance to imatinib: (A) OXPHOS protein expression is increased in IM-resistant GIST cells, and IM specifically increases the expression of complex II (SDH) protein by downregulating miR-483-3p. (B) GLUT-1 and glycolytic pathway components increase in IM-resistant GIST cells. (C) The HIF-1α–PGD–PPP axis and IM-induced ROS stimulate GIST cells from the G1 phase to the S phase, leading to drug resistance.
downstream signaling pathways, such as the PI3K/AKT/mTOR pathway, and continue to drive GIST proliferation and survival, leading to acquired IM resistance (23–27). KIT T670I is one of the most common types of secondary KIT mutations (24). Cassier et al. found that PDGFRα exon 18 D842V gene subtype mutation is associated with primary resistance to IM (16). Secondary PDGFRα mutations are less common in IM-resistant GISTs than secondary KIT mutations (28, 29). Secondary KIT mutations or PDGFRα mutations do not occur in wild-type IM-resistant GISTs (30).

In a previous study of 210 Chinese patients with IM-resistant GIST who underwent next-generation sequencing for the identification and characterization of secondary KIT mutations, the results showed that 63.81% of the patients had mutations on exon 13, 4.76% had mutations on exon 14, and 31.43% had mutations on exon 17. All secondary KIT mutations were missense mutations, mostly located in the kinase domain (31). Zhao et al. obtained consistent results in an analysis of the distribution of the most common Kit mutation forms in 2,273 Chinese patients with GIST. The results showed that KIT exon 13 V654A and exon 17 N822K were the most common secondary mutations in GISTs with primary mutations in exon 11 (32). These two secondary KIT mutations induce resistance to IM by activating the PI3K/AKT/mTOR pathway (33). Inhibition of PI3K induces massive apoptosis in IM-resistant GISTs (34). Interestingly, KIT is overactivated in IM-resistant GISTs with secondary KIT mutations; however, the expression levels are not significantly increased. Secondary PDGFRα mutations are mostly located in exon 18 (24, 35).

In addition to secondary KIT and PDGFRα mutations, several additional genetic mutations have been associated with secondary resistance to IM in GISTs. Additional mutations of RB1, SMARCB1, and MAX (myc-related protein) are important causes of resistance to IM. Notably, GISTs caused by different gene mutations show different clinicopathological characteristics (31). Genome-scale CRISPR-Cas9 knockout (GeCKO) screening classifies TP53 and SOCS6 as candidate genes for resistance to IM owing to their presence in multiple signaling pathways, such as the apoptosis pathway, Wnt signaling pathway, and JAK-STAT signaling access (36).

Identifying the abovementioned types of gene mutation is a key supplement to the existing GIST risk assessment model. In addition, the discovery of new potential candidate therapeutic targets for different genetic mutations will be beneficial in delaying the progression of GISTs. Individualized therapy based on the identification of types of genetic mutation will also provide new adjuvant treatment options for patients with IM-resistant GIST. Furthermore, the type of gene mutation may be used as a biomarker to help identify patients who can benefit more from adjuvant therapy and to predict the risk of recurrence of GISTs.

### 2.2 Abnormal energy metabolism and resistance to imatinib

An important feature of cancer cells is abnormal energy metabolism, which is characterized by strong aerobic glycolysis and reduced mitochondrial energy metabolism. This feature is called the Warburg effect (37). Metabolic reprogramming of cancer cells sets the stage for rapid growth and metastasis (38, 39). Drug-resistant cancer cell subsets depend on the enhancement of mitochondrial function and OXPHOS (40, 41). Moreover, the metabolic adaptation of cancer cells to the toxic effects of targeted drugs contributes to drug resistance (42–45). GIST cells exhibit high levels of glucose uptake and aerobic glycolytic activity, and metabolic reprogramming induced by IM stress enhances mitochondrial function and OXPHOS (46).

IM alters the metabolic phenotype of GISTs (46) and increases the expression of several OXPHOS proteins, including complexes II, III, and V (40). Huang et al. found that IM-resistant GIST cells show increased OXPHOS protein expression compared with IM-sensitive GIST cells (Figure 1A) (40). In addition, IM-resistant GIST cells show higher OXPHOS levels and glycolysis rates than IM-sensitive cells and are more susceptible to glycolysis inhibition. Inhibition of OXPHOS increases the sensitivity of GISTs to IM. OXPHOS protein expression is increased in IM-sensitive GIST cells after IM treatment but not in IM-resistant GIST cells (47). Notably, there is a heterogeneity of metabolic phenotypes in IM-resistant GIST (40). Glucose transporter 1 (GLUT-1) is a key component of the glycolytic pathway and is associated with secondary resistance to IM in GIST cells. IM downregulates the expression of GLUT-1 and the glycolytic pathway components hexokinase 2, pyruvate kinase M2, and lactate dehydrogenase in IM-sensitive GIST cell lines. In contrast, the expression of GLUT-1 and these glycolytic pathway components increases after the treatment of IM-resistant GIST cell lines using IM (Figure 1B). This indicates that IM-resistant GIST cells have a higher glycolysis rate than IM-sensitive GIST cells (48).

Following chronic IM induction, energy metabolism in GIST cells shifts from the tricarboxylic acid cycle to the pentose phosphate pathway (PPP) (47). On one hand, the expression of phosphate glucose dehydrogenase (PGD), one of the rate-limiting enzymes of the PPP, is significantly upregulated in IM-resistant GIST cell lines. Overexpression of PGD promotes GIST cell proliferation and inhibits cell apoptosis. On the other hand, the level of hypoxia-inducible factor 1α (HIF-1α) is elevated under prolonged stimulation of reactive oxygen species generated by IM (47). HIF-1α leads to changes in metabolic pathways as follows: the HIF-1α–PGD–PPP axis stimulates GIST cells from the G1 phase to the S phase, inhibits GIST cell apoptosis through metabolic reprogramming, and ultimately leads to IM resistance (Figure 1C) (47).
Most of the research viewpoints on energy metabolism in GIST cells have reached a consensus, which provides a theoretical basis for overcoming resistance to IM from the perspective of abnormal energy metabolism. Therapy involving the inhibition of the energy metabolism pathway combined with IM, such as VLX600 combined with IM and WZB117 combined with IM, requires further preclinical validation (46, 48).

2.3 Non-coding RNAs and resistance to imatinib

2.3.1 Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides with no or limited protein-coding capacity (49–51). LncRNAs play key roles in several important biological processes, including regulation of epigene expression, as well as transcriptional and posttranscriptional regulation (52). Numerous studies have demonstrated that lncRNAs play key regulatory roles in the disease course of human cancers, including cancer cell proliferation, apoptosis, and drug resistance (53–55). In addition, recent studies have shown that lncRNAs can modulate the sensitivity of patients to anticancer drugs and thus have the potential to be therapeutic targets in the treatment of drug-resistant tumors (56, 57). Moreover, lncRNAs may promote the progression and metastasis of GISTs, and the expression of many lncRNAs in primary GIST tissue differs from that in recurrent GIST tissue (58, 59). Furthermore, lncRNAs are associated with secondary resistance to IM in GISTs, and the resistance mechanisms are mostly related to signaling pathways (60–63). LncRNAs, such as the HOX antisense intergenic RNA (HOTAIR), can also promote IM resistance by activating autophagy in GIST cells (62).

The lncRNA coiled-coil domain-containing 26 (CCDC26), located on chromosome 8q24.21, is a retinoic acid–dependent regulator of myeloid differentiation, also known as RAM (64). CCDC26 interacts with C-KIT and regulates its transcription. In addition, CCDC26 downregulates the expression of c-Kit in GISTs, whereas CCDC26 knockout induces IM resistance in GIST cells by upregulating the expression of C-KIT (Figure 2A) (60). CCDC26 knockout also upregulates the expression of insulin-like growth factor 1 receptor (IGF-1R) (Figure 2A). IGF-1R induces drug resistance by participating in the apoptosis pathway (Figure 2C), whereas inhibition of IGF-1R reverses CCDC26 knockout–induced drug resistance (59, 65, 66). These findings suggest that treatment targeting the CCDC26 or
CCDC26-IGF-1R axis may improve sensitivity to IM in patients with IM-resistant GISTs.

Yan et al. identified a set of dysregulated lncRNAs in IM-resistant GISTs using chip technology and found that lncRNAJC6-2 is associated with the HIF-1α pathway, which links lncRNAs to energy metabolism (61). Using high-throughput RNA sequencing, Shao et al. found that GIST samples express 40% of all annotated lncRNAs in humans. Notably, the number of downregulated lncRNA expressions was greater than the number of upregulated expressions, irrespective of the presence or absence of resistance to IM. The expression of RP11616M22.7 is significantly increased in IM-resistant samples than that in non-resistant samples and is closely related to the Hippo pathway. Overexpression of RP11616M22.7 induces resistance to IM in GIST cells, whereas RP11616M22.7 gene knockout enhances IM resistance in GIST cells both in vitro and in vivo (62).

Some studies have demonstrated that the expression and dysregulation of lncRNAs are more cancer-specific than those of protein-coding genes (67). Therefore, specific lncRNAs in GISTs are likely to be involved in unique biological functions related to treatment and drug resistance. With an in-depth exploration of specific lncRNAs and their mechanisms, our understanding of the non-coding transcriptome of GISTs will become more comprehensive, which will, in turn, accelerate the development of new effective therapeutic targets.

2.3.2. MicroRNAs

MicroRNAs (miRNAs) are 22-nucleotide non-coding small ribonucleic acids that control tumor cell growth by regulating the expression of multiple gene products and the function of cellular pathways (68). MiRNAs play important roles in the pathogenesis, invasion, and drug resistance of tumors and are thus identified as targets for cancer diagnosis, therapy, and prognosis (69–72). Akçakaya et al. analyzed miRNA expression profiles to study the miRNA expression signatures associated with response to IM and KIT mutation status in patients with GIST. They found that miR-125a-5p and its target gene, tyrosine-protein phosphatase non-receptor type 18 (PTPN18), play important roles in IM resistance. The mechanism behind this is that overexpression of miR-125a-5p downregulates the level of PTPN18 expression in GISTs and promotes resistance to IM (73). Subsequent studies demonstrated that the effects of miR-125a-5p and PTPN18 on IM resistance are mediated through phosphorylated FAK levels (Figure 3) (28). By comparing two groups of IM-resistant GIST samples with and without secondary mutations, Amirnasr et al. detected 22 significantly differentially expressed miRNAs and almost completely separated the two groups of samples. Three of these miRNAs, namely, miR-92a-3p, miR-99a-5p, and miR-101-3p, are potential effectors of IM resistance. This suggests that the distribution of miRNA biomarkers may be related to the presence of secondary mutations (74). Zhang et al. used

![FIGURE 3](image-url)
Overexpression of miR-125a-5p downregulates the expression of PTPN18 and promotes IM resistance in GISTs mediated by phosphorylated FAK levels.
themicroarray data preserved by Akcakaya et al. to identify five key miRNAs in the lncRNA–miRNA target gene regulatory network, confirming that overexpression of miR-28-5p and miR-125a-5p is significantly related to secondary resistance to IM (75). Kou et al. studied the miRNA expression profiles in the sera of patients with GIST and found that the levels of miR-518e-5p and miR-548e in the sera of the patients in the IM-resistant group were significantly higher than those of the patients in the IM-sensitive and healthy control groups. This indicates that the serum level of miR-518e-5p can distinguish IM-resistant patients from IM-sensitive patients or healthy individuals (76).

Studies have demonstrated that miRNAs can regulate resistance to chemotherapy by inducing autophagy in GIST cells (77, 78). Chen et al. found that miR-30a sensitizes GIST cells to IM by inhibiting autophagy and confirmed that the autophagy marker Beclin-1 is a target gene of miR-30a (79). Zhang et al. found that HOTAIR targeting the autophagy-related protein 2 homolog B inhibitor miR-130a promotes resistance to IM by upregulating the level of autophagy (63).

Information regarding most miRNAs associated with secondary resistance to IM is still in the discovery stage; thus, the resistance mechanisms need to be studied further. Because miRNAs are closely related to the pathogenesis, invasion, metastasis, and drug resistance of tumors, research ideas should be broadened rather than limited to one aspect. Several studies have confirmed that lncRNAs can regulate other non-coding RNAs, especially miRNAs, and that miRNAs also have regulatory effects on lncRNAs (80, 81). Therefore, improving the regulatory network of miRNAs and lncRNAs in IM-resistant GISTs is also a promising research direction.

### 2.4. Several key proteins and resistance to imatinib

From a protein perspective, approximately 10% of KIT-positive GISTs lose the expression of KIT oncoproteins and become resistant to TKIs owing to the transition to a KIT-independent state (KIT-negative) during TKI treatment (82). Tu et al. found that Axl in TKIs is highly expressed in KIT-negative GISTs and that Axl gene knockout or silencing can inhibit the proliferation of KIT-negative GISTs. This information provides a new perspective regarding the Axl/P53 signaling axis as a therapeutic target for a subset of KIT-negative GISTs (83).

Cyclin D1 can regulate the cell cycle through the activation of the cyclin-dependent kinase (CDK), activation of transcription factors, RAD51 co-regulation of DNA repair, and activation of the AMPK-LKB1 signaling pathway (84). Cyclin D1 is highly expressed in each KIT-independent GIST cell subtype. In addition, inhibition of cyclin D1 has antiproliferative and proapoptotic effects in KIT-independent GISTs, which are associated with Rb activation and p27 upregulation. Notably, PRKCQ is a negative regulator of cyclin D1 expression, whereas the Jun and Hippo pathway effector molecules YAP and TAZ are positive regulators of cyclin D1 expression. The PRKCQ, Jun, and Hippo pathways synergistically regulate cyclin D1 expression in GISTs (85). Using GeCKO screening, (85) found that CDKI is highly expressed in advanced and IM-resistant GISTs in three patient cohorts. CDKI is the founding member of the CDK family (86). It can promote the proliferation and progression of GISTs by binding to substrate protein kinase B (Akt) and regulating its phosphorylation (87). In most solid tumors, Aurora kinase A (AURKA) promotes cell cycle progression by regulating cell cycle checkpoints (88). A clinical analysis has demonstrated that AURKA can be an independent prognostic factor for GISTs. In addition, experiments have shown that overexpression of AURKA can promote the proliferation of GIST-T1 cells, inhibit cell apoptosis, and enhance the resistance of cells to IM (89).

Several multidrug transporters play key roles in secondary drug resistance by regulating drug concentrations in tumor cells. Multidrug resistance–related protein 1 (MRP1) is one of the major multidrug transporters (90). Intracellular IM level plays an important role in the development of IM resistance in patients with chronic myeloid leukemia (91). Studies have confirmed that MRP1 and breast cancer resistance protein are highly expressed in IM-resistant GIST cell lines and that IM-resistant patients with GIST show significantly lower intracellular IM levels than IM-sensitive patients (92). This suggests that drug transporters may play an important role in IM resistance. Xu et al. proposed the following mechanism for this: the methyltransferase METTL3 mediates 6-methyladenosine (M6A) to modify the 5’end non-coding region of the multidrug transporter MRP1 mRNA and promotes the translation of MRP1 mRNA, leading to drug resistance in GISTs (93). M6A is a common mRNA modification that regulates mRNA stability, splicing, and translation (94, 95). These findings suggest that drug transporters may be potential therapeutic targets in the treatment of IM-resistant GISTs.

The insulin receptor (IR) is a member of the tyrosine kinase family, including homologous types 1 and 2 (IGF-1R and IGF-2R) (96). IR and IGF-1/2R play important roles in energy metabolism and cell growth, division, and differentiation (97). Chen et al. showed that IR and Kit are co-activated in IM-resistant GIST cells and biopsy samples but not in IM-sensitive GIST cells (Figure 2A). They also found that additive antiproliferative and proapoptotic effects were obtained after the combined inhibition of IR and KIT in IM-resistant GIST cells (Figure 2B) (98). Thus, the inactivation of IR increases the sensitivity of resistant cells to IM, suggesting that the combined inhibition of IR and KIT is a promising therapeutic strategy in the treatment of IM-resistant GISTs.

Serrano-Candelas et al. found that the linker molecule SH3-binding protein 2 (SH3BP2) is expressed in non–wild-type GISTs. SH3BP2 is involved in the regulation of the expression of...
and cellular activity of KIT and PDGFRA in GISTs. They also found that silencing of SH3BP2 is accompanied by downregulation of oncogenic KIT and PDGFRA and significant promotion of apoptosis in IM-sensitive and resistant GIST cells (99).

The relationship between various key proteins and IM resistance mechanisms is intricate and interconnected. However, there is no clear comparison of the role of each protein network in the mechanism of resistance to IM. Targeted therapy that involves a single protein network may not solve the problem of secondary resistance to IM. The combined inhibition of multiple protein networks may become a new research direction for the treatment of IM-resistant GISTs.

2.5. Mutation and other gene aberrations and resistance to imatinib

2.5.1. Oncogenic KIT signaling on the Golgi apparatus

The Golgi apparatus may serve as a platform for oncogenic KIT signaling (100, 101). Moreover, oncogenic KIT signaling on the Golgi apparatus is essential for the autonomous proliferation of GIST cells (101). In IM-resistant GISTs with secondary KIT mutations, oncogenic KIT signaling is predominantly localized to the Golgi apparatus (100). This KIT activates the PI3K/AKT/mTOR pathway, MEK-Erk pathway, and signal transducer and activator of transcription 5 (Figure 4) (100). Blocking KIT biosynthetic transport from the endoplasmic reticulum to the Golgi apparatus suppresses oncogenic signaling, suggesting that Kit autophosphorylation is spatiotemporally regulated (100, 101). In an analysis of this mechanism, Obata et al. discovered a biosynthetic protein, 2-methylcopropylamide (M-COPA; also known as “AMF-26”), which blocks the transport of KIT from the endoplasmic reticulum to the Golgi apparatus by inhibiting the autophosphorylation of KIT at Y703/Y721/Y730/Y936 and ultimately inhibits oncogenic KIT signaling (Figure 4) (101). M-COPA inhibits the activation of Kit kinase domain mutants, thereby inhibiting the proliferation of IM-resistant GISTs (101). A novel heat shock protein 90 inhibitor, TAS-116, also inhibits the growth of drug-resistant cells and induces their apoptosis by reducing KIT autophosphorylation in the Golgi apparatus (102). Notably, the effect of TAS-116 has been validated in an animal study conducted using a xenograft mouse model (102).

Oncogenic KIT signaling on the Golgi apparatus provides new insights into not only the pathogenesis of KIT but also the treatment of IM-resistant GISTs that express mutant KIT. However, further studies are needed to confirm the clinical efficacy of drug therapies that target this carcinogenic signal.

---

**FIGURE 4**
Model of oncogenic KIT signaling on intracellular compartments in GISTs. KIT is normally transported from the endoplasmic reticulum to the Golgi apparatus, followed by full glycosylation. After reacting with the Golgi apparatus, KIT can activate the PI3K/AKT/mTOR pathway, MEK-Erk pathway, and STAT5. M-COPA inhibits oncogenic signaling by blocking the transport of KIT from the endoplasmic reticulum to the Golgi because KIT activates downstream molecules only on the Golgi apparatus.
2.5.2. KIT\textsuperscript{low} cell subsets

KIT\textsuperscript{low} cell subsets may be a cell bank that mediates the progression and recurrence of GISTs (103). Bardsley et al. detected a precursor cell of ICCs in the stomach wall of a mouse that possesses stem cell properties, including the ability to self-renew and differentiate into mature ICCs. This ICC precursor cell–derived cell line was able to spontaneously transform to form GIST-like tumors. Notably, the expression of Kit in this ICC precursor cell was lower than that in mature ICC precursor cells (104, 105).

Inherently, IM-resistant CD34\textsuperscript{KITlow} cells are a distinct subset of GIST cells. KIT\textsuperscript{low} cells have stronger replication ability and clonogenic potential than KIT\textsuperscript{High} cell subsets. This subpopulation has tumor stem cell–like expression characteristics and behaviors and can self-renew and differentiate into IM-sensitive CD34 KIT\textsuperscript{High} progeny. Notably, TKI treatment results in the enrichment of this KIT\textsuperscript{low} cell subset, which may be mediated by cell-associated transcription factors (OCT4 and NANOG) (103). The KIT\textsuperscript{low} cell subset represents a novel mechanism of primary resistance to TKIs and a targetable subpopulation in the treatment of GISTs. This provides valuable therapeutic ideas for overcoming the persistence and recurrence of GISTs after TKI therapy.

3 Conclusions

In this review, the findings of studies on mechanisms of secondary resistance conducted over the last 5 years are summarized from the aspects of abnormal energy metabolism, gene mutations, non-coding RNA, and key proteins. These previous studies provide theoretical support for solving the problem of the mechanism of resistance to IM. However, the available data on most drug-resistance mechanisms are still in the research stage. Further clinical studies are needed to confirm the safety and efficacy of utilizing drug-resistance mechanisms as potential therapeutic targets.

Addressing the problem of secondary resistance to IM has always been the key to improving the treatment outcomes and prognoses of patients with GISTs. Different resistance mechanisms are closely linked and interact with each other; thus, using a single resistance mechanism as a therapeutic target should be avoided. The combined inhibition of drug-resistance mechanisms with IM therapy and the combined inhibition of multiple drug-resistance mechanisms are expected to become new options in the treatment of GISTs. Implementing individualized therapy based on the identification of resistance mechanisms will provide new adjuvant treatment options for patients with IM-resistant GISTs, thereby delaying the progression of GISTs.

Author contributions

Conceptualization: ZW. Article collection and analysis: YK, XH, PS, and QZ. Manuscript writing: XH and QZ. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81601692), the Technology Research from the Department of Education of Liaoning Province (No. JCRZ20200013), and the 345 Talent Project of Shengjing hospital of China Medical University.

Acknowledgments

The authors would like to thank all the reviewers who participated in the review and also Editage (www.editage.cn) for its linguistic assistance during the preparation of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol (2002) 3 (11):655–64. doi:10.1016/S1470-2045(02)00899-9

2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol (2006) 23(2):70–83. doi:10.1053/j.semdp.2006.09.001
3. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. *Lancet* (London Engl) (2007) 370(9607):1731–41. doi: 10.1016/S0140-6736(07)60708-6.

4. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. *Lancet* (London Engl) (2013) 382(9896):973–83. doi: 10.1016/S0140-6736(13)60610-6.

5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Sci. New York* (2000) 289(5485):49–54. doi: 10.1126/science.289.5485.49.

6. Wozniak A, Gebeleynanne YK, Debrec-Rychter M, Schöffski P. New targets and therapies for gastrointestinal stromal tumours. *Expert Rev Anticancer Ther* (2017) 17(12):1117–29. doi: 10.1080/14747696.2017.1400386.

7. Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. *Cancer Res* (2007) 67(19):9084–8. doi: 10.1158/0008-5472.CAN-07-1938.

8. Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. *Hematol Oncol Clinics North America* (2009) 23(1):15–34. doi: 10.1016/j.hc.2008.11.005.

9. Urbani M, Astolfi A, Indio V, Nannini M, Schipani A, Bacalini MC, et al. Gene duplication, rather than epigenetic changes, drives FGFR overexpression in KIT/PDGFRα wild-type GIST. *Sci. Rep.* (2020) 10(1):19829. doi: 10.1038/s41598-020-76519-y.

10. Astolfi A, Indio V, Nannini M, Saponara M, Schipani A, De Leo A, et al. Targeted deep sequencing uncovers cryptic KIT mutations in KIT/PDGFRA/SDH-A-p-wild-type GIST. *Front Oncol* (2020) 10:15054. doi: 10.3389/fonc.2020.00504.

11. Kays JK, Soin JD, Kim BJ, Goze K, Koniari LG. Approach to wild-type gastrointestinal stromal tumours. *Trans Gastroenterol Hepatol* (2018) 3(2):192. doi: 10.21037/tgh.2018.10.13.

12. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. *Am J Pathol* (2004) 165(1):107–13. doi: 10.1016/S0002-9440(04)03279-8.

13. Espinosa L, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. *Am J Surg Pathol* (2008) 32(7):210–8. doi: 10.1097/PAS.0b013e3181b238ec.

14. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, et al. Approach to wild-type gastrointestinal stromal tumors. *New Engl J Med* (2002) 347(7):472–8. doi: 10.1056/nejmoa012090.

15. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and predictive implications. *Front Oncol* (2013) 3(8):10600. doi: 10.3389/fonc.2013.01060.

16. Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, et al. Analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. *Mol Cancer* (2008) 9:61. doi: 10.3389/fonc.2008.00617.

17. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Molecular subtypes of gastrointestinal stromal tumors. *Expert Rev Anticancer Ther* (2016) 17(12):1117–9. doi: 10.1080/14737140.2016.1100386.

18. Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, et al. Identifying secondary mutations in imatinib-resistant gastrointestinal stromal tumors. *J Clin Oncol* (2009) 27(18):2964–70. doi: 10.1200/JCO.2008.16.1211.

19. Raul PJ, Berg RC, Moskaluk CA, Leach SD, Iafrate AJ, Livingston DM, et al. Identification of secondary mutations in imatinib-resistant gastrointestinal stromal tumors. *Mol Cancer* (2010) 9:31. doi: 10.1186/1476-4598-9-31.

20. Huang WK, Ackerley P, Gangavet A, Lee L, Zelik J, Hajeri P, et al. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. *Exp Cell Res* (2018) 371(1):287–96. doi: 10.1016/j.yexcr.2018.08.012.

21. Rémi KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. *J Clin Oncol* (Northwood London England) (2008) 26(2):207–13. doi: 10.1002/jc.21828.

22. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up. *JAMA Oncol* (2020) 6(8):1241–6. doi: 10.1001/jamaoncol.2020.2091.

23. Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Gloebbeke M, Debrec-Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumours in the tyrosine kinase inhibitor era. *Clin Cancer Res* (2012) 18(16):4458–64. doi: 10.1158/1078-0432.CCR-11-3025.

24. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. *J Clin Oncol* (2013) 31(16):1999–2005. doi: 10.1200/JCO.2012.41.5573.

25. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncoprotein-dependent mechanisms of resistance to imatinib in gastrointestinal stromal tumors: PI3 kinase/AKT is a crucial survival pathway. *Oncogene* (2007) 26(54):7560–8. doi: 10.1038/sj.onc.1210558.

26. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol* (2006) 24(29):4764–74. doi: 10.1200/JCO.2006.06.2265.

27. Cao J, Wei J, Yang P, Zhang T, Chen Z, He F, et al. Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumour with imatinib resistance. *Mol Cancer* (2018) 17(11):121. doi: 10.1186/s12943-018-0865-2.

28. Warburg O. On respiratory impairment in cancer cells. *Sci (New York)* (1956) 125(3251):679–90. doi: 10.1126/science.125.3215.269.

29. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. *Cancer Cell* (2013) 23(6):811–25. doi: 10.1016/j.ccr.2013.05.003.

30. Nature (2014) 514(7524):628–32. doi: 10.1038/nature13611.
cholangiocarcinoma. gemcitabine sensitivity by modulating FOXO3 phosphorylation in gutjnl-2019-318903 non-coding RNA in colorectal cancer.

by sponging miR-331-3p in gastric cancer.

1476-4598-13-92 Genetics future.

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651

13059-017-1348-2 Genet. Mol Cell (2008) 640(1-2):97

147-185-13-92 Cancer Res (2013) 142(4):651–69. doi: 10.115344.142.651
87. Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y, et al. Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res (2021) 81(9):2481–94. doi: 10.1158/0008-5472.CAN-20-3580
88. Yan M, Wang C, He B, Yang M, Tong M, Zong L, et al. Aurora-a kinase: A potent oncogene and target for cancer therapy. Med Res Rev (2016) 36(6):1036–79. doi: 10.1002/med.21399
89. Cheng X, Wang J, Lu S, Fan W, Wang W. Aurora kinase a (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors. Cancer Cell Int (2021) 21(1):407. doi:10.1186/s12935-021-02111-7
90. Fletcher JI, Williams RT, Henderson MJ, Norris MD, Haber M. ABC Transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updates: Rev commentaries antimicrobial Anticancer chemother (2016) 26:1–9. doi:10.1016/j.drup.2016.03.001
91. Widmer N, Rumpold H, Untergasser G, Fayet A, Buzin T, Decosterd LA. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia (2007) 21(7):1561–2. doi: 10.1038/sj.leu.2404671
92. Zhang Q, Li Z, Xu K, Qian Y, Chen M, Li B, et al. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor. Scand J Gastroenterol (2019) 54(2):220–6. doi: 10.1080/00365521.2019.1577488
93. Xu K, Zhang Q, Chen M, Li B, Wang N, Li C, et al. N(6)-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRPI. Cancer Lett (2022) 530:85–99. doi: 10.1016/j.canlet.2022.01.008
94. Wang X, Zhao BS, Roundtree 1A, Lu Z, Han D, Ma H, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell (2015) 165(6):1388–99. doi: 10.1016/j.cell.2015.05.014
95. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature (2014) 505(7481):117–20. doi:10.1038/nature12730
96. Arcaro A. Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 4:30. doi: 10.3389/fphar.2013.00030
97. Menting IG, Whittaker I, Margetts MB, Whittaker LJ, Kong G, Smith BJ, et al. How insulin engages its primary binding site on the insulin receptor. Nature (2013) 493(7431):241–5. doi: 10.1038/nature12781
98. Chen W, Kuang Y, Qu HB, Cao Z, Tu Y, Sheng Q, et al. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res (2017) 77(18):5107–17. doi: 10.1186/0008-5472.CAN-17-0917
99. Serrano-Canedelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodríguez P, García-Valverde A, Bazzocco S, et al. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRα receptors expression and impairs gastrointestinal stromal tumors growth. Mol Oncol (2018) 12(8):1383–97. doi: 10.1002/1878-0261.12332
100. Obata Y, Horikawa K, Takahashi T, Akieda Y, Tsujimoto M, Fletcher JA, et al. Oncogenic signaling by kit tyrosine kinase occurs selectively on the golgi apparatus in gastrointestinal stromal tumors. Oncogene (2017) 36(26):3661–72. doi: 10.1038/onc.2016.519
101. Obata Y, Horikawa K, Shiina I, Takahashi T, Murata T, Tasaki Y, et al. Oncogenic kit signalling on the golgi is suppressed by blocking secretory trafficking with m-COPA in gastrointestinal stromal tumours. Cancer Lett (2018) 415:1–10. doi: 10.1016/j.canlet.2017.11.032
102. Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, et al. TAS-116 inhibits oncogenic KIT signalling on the golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours. Br J Cancer (2020) 122(3):658–67. doi: 10.1038/s41416-019-0668-y
103. Banerjee S, Yoon H, Ting S, Tang CM, Yebra M, Wenzel AT, et al. Kit (low) cells mediate imatinib resistance in gastrointestinal stromal tumor. Mol Cancer Ther (2021) 20(10):2035–48. doi: 10.1158/1535-7163.MCT-20-0973
104. Bardesley MR, Hervéth VJ, Asuzu DT, Lorincz A, Redelman D, Hayashu Y, et al. Kitlow stem cells cause resistance to kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology (2018) 139(3):942–52. doi: 10.1053/j.gastro.2010.05.083
105. Lorincz A, Redelman D, Hervéth VJ, Bardesley MR, Chen H, Ordóñez T. Progenitors of intestinal cells of cajal in the postnatal murine stomach. Gastroenterology (2008) 134(4):1083–93. doi: 10.1053/j.gastro.2008.01.036